Dr. Radha Duttagupta brings over 15 years of experience in test development, trial strategy and pre- and post-market studies for LDT/RUO/IVD products in the clinical diagnostic industry. Currently serving as the Vice President of Clinical Affairs at Nucleix, she is helping drive the clinical strategy around the development of a lung cancer screening test.
Prior to Nucleix, Radha served as Director of Clinical Operations and Clinical Development at Karius driving the clinical validity, utility and publication strategy for the Karius® Test (liquid biopsy for infectious diseases) in immunocompromised patients suspected with pneumonia. Radha has held previous positions at Cepheid (Danaher) leading clinical trials in the ID portfolio including Xpert® Xpress MVP, Xpert® MTB/XDR (molecular DST for Extreme Drug Resistance TB) and Affymetrix (part of Thermofisher Scientific) in product and clinical development of pre and post-natal tests for copy number (CN) detection spanning CytoScan™ XON, CytoScan™ Optima and CytoScan™ Dr. Radha has a Ph.D in Biochemistry and Molecular Genetics from Rutgers University and University of Medicine and Dentistry of New Jersey (UMDNJ), Robert Wood Johnson Medical School, New Jersey and was a post-doctoral fellow in the Transcriptome group at Affymetrix.